Release Kinetics in PRF Versus GEM21S with and Without Bone Substitutes: an in Vitro Analysis

Launched by UNIVERSITY OF ALABAMA AT BIRMINGHAM · Jul 6, 2021

Keywords

ClinConnect Summary

This clinical trial is looking at how certain proteins, called platelet-derived growth factor-BB (PDGF-BB), help with healing bone loss. PDGF-BB is important for wound healing, and this study is comparing two different treatments: Platelet Rich Fibrin (PRF) and a commercial product called GEM21S. The researchers want to see if combining GEM21S with a bone graft can improve healing better than using PRF alone.

To participate in this trial, you need to be at least 18 years old, speak English, and be in good health without any smoking habits or medications that could affect healing. If you join, you'll be part of a study that is currently active but not recruiting new participants. This means that while the study is ongoing, they are not looking for new volunteers at this time. If you meet the eligibility criteria, this could be a chance to contribute to important research on better ways to treat bone loss.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • English speaking
• • At least 18 years old
• • Able to read and understand informed consent document
• • Systemically healthy, non-smoker, no medications
• Exclusion Criteria:
• • Non-English speaking
• • Less than 18 years old
• • Smokers/tobacco users (\>10 cigarettes/day)
• • Patients with systemic pathologies or conditions contraindicating oral surgical procedures or adversely affecting healing